Blood and tumor tests aim to predict prostate cancer treatment success
NCT ID NCT07050433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people already in the SYNERGY-201 trial, which tests a drug combination for prostate cancer. Researchers want to see if a marker called CXCR2 can predict who will respond well to the treatment. Blood samples and optional tumor biopsies will be collected over time to track changes in these markers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
RECRUITINGDurham, North Carolina, 27705, United States
-
Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109-2800, United States
Contact Email: •••••@•••••
-
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?